A new chemical compound that uses bio-orthogonal click chemistry to target tumor cells while sparing healthy cells has entered clinical trials.
The United States’ global leadership on science technology faces formidable competition from the People’s Republic of China; however the U.S. can take actions to maintain its competitive edge while enhancing innovation and protecting national security, according to a new report from the University of California San Diego.
Pearls have long been favored as objects of beauty. Now, Purdue University innovators are using the gem to provide potential new opportunities for spectral information processing that can be applied to spectroscopy in biomedical and military applications.
Researchers from Kumamoto University (Japan) have developed a system to quickly and easily measure the antioxidant capacity of food.
Plastomics Inc., an agricultural biotech start-up developing the next generation of trait delivery technology, has been awarded a competitive grant from the United Soybean Board (USB) to develop disease resistant soybeans.
Argonne scientists, working as part of a national consortium of structural genomics experts, have greatly increased our knowledge of the virus that causes COVID-19.
A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has invented an artificial olfactory system that mimics the mammalian nose to assess the freshness of meat accurately.
Prof. Rotem Sorek’s lab at the Weizmann Institute of Science has revealed the role retrons play in bacteria, finding that the hybrid structures are immune system guards that ensure the bacteria’s survival when it is infected by viruses. In addition, the team hopes that newly identified retrons will improve genome-editing tools.
A simple COVID-19 test kit combines virus amplification with a CRISPR-Cas system for effective SARS-CoV-2 detection. The kit, called iSCAN, uses reagents that can be locally manufactured.
There have been many documented cases of Covid-19 "super-spreading" events, in which one person infected with the SARS-CoV-2 virus infects many other people.
FAU's Herbert Weissbach, Ph.D., recently received BioFlorida’s “Lifetime Achievement Award,” reserved to recognize outstanding leadership in the industry throughout an individual’s career and for significant contributions to industry growth.
Purdue University innovators are taking cues from nature to develop 3D photodetectors for biomedical imaging.
Embody, Inc., a privately-held medical device company developing novel collagen-based technologies for sports medicine and soft tissue repair, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TAPESTRY Biointegrative Implant for tendon and ligament repair.
A virtual symposium to highlight the impact the U.S. Department of Energy's (DOE) National Virtual Biotechnology Laboratory (NVBL) has had utilizing the unique capabilities of the DOE to tackle the science and technology challenges associated with COVID-19, and to discuss areas in which the NVBL can have impact in the future. The event is aimed at the S&T community, media, and the general public.
The CSU Program for Education and Research in Biotechnology (CSUPERB) continues to prepare students for California’s growing biotechnology workforce in several disciplines across all 23 campuses.
Researchers at Canada's McMaster University and SQI Diagnostics have created a surface that repels every other element of human blood except a critical indicator of infection, opening a timely window for understanding the progress of COVID-19 in individual patients.
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right